Treatment of Chronic Lymphocytic Leukaemia with Anti-Idiotypic Antibody
Author Information
Author(s): J. Gordon, A.K. Abdul-Ahad, T.J. Hamblin, F.K. Stevenson, G.T. Stevenson
Primary Institution: Lymphoma Research Unit, Tenovus Research Laboratory, General Hospital, Southampton, UK
Hypothesis
Can polyclonal anti-idiotypic antibodies effectively treat chronic lymphocytic leukaemia (CLL)?
Conclusion
The study found that while some patients showed a decrease in lymphocyte counts after treatment, the counts rebounded quickly, indicating challenges in effectively targeting leukaemic cells.
Supporting Evidence
- Three out of four patients showed a significant drop in lymphocyte counts after treatment.
- Cell counts rebounded to near pre-infusion levels within a week.
- Viable lymphocytes showed evidence of antigenic modulation after antibody infusion.
Takeaway
Doctors tried to use special antibodies to help patients with a type of blood cancer, but the cancer cells kept coming back.
Methodology
Patients received infusions of polyclonal anti-idiotypic antibodies, and their blood lymphocyte counts were monitored.
Limitations
The study involved a small number of patients and did not observe significant tumor mass reduction.
Participant Demographics
Four patients with chronic lymphocytic leukaemia, including three males and one female, aged between 53 and 76.
Want to read the original?
Access the complete publication on the publisher's website